ReviewCytoJournal2022
Cancer cervix: Epidemiology and disease burden.
Review in CytoJournal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 3 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis.Journal of gynecologic oncology · 2026Pooled it
- What are the views and experiences of human papillomavirus (HPV) self-sampling for cervical screening in high-income countries? A qualitative systematic review using the Theoretical Domains Framework.BMC public health · 2026Pooled it
- Effectiveness ofThe Journal of international medical research · 2025Pooled it
- Real-world safety data of human papillomavirus vaccines after marketing in Shandong, China, August 2017-October 2025.Human vaccines & immunotherapeutics · 2026Article
- From HPV infection to cervical precancer: Molecular mechanisms, immune microenvironment and emerging technologies.Cellular and molecular life sciences : CMLS · 2026Review
- Clinical efficacy and outcomes of enhanced recovery after surgery for laparoscopic cervical cancer.Biomedical reports · 2026Article
- Efficacy of the swede score in optimizing triage of visual inspection with acetic acid positive women: cross-sectional evidence from Bangladesh.Annals of medicine and surgery (2012) · 2026Article
- Integrated transcriptomic and functional analysis reveals selective cytotoxicity and HPV oncogene suppression induced by cinnamon essential oil in cervical cancer cells.BMC complementary medicine and therapies · 2026Article
- Article
- Navigating the divide - demographic and individual predictors of low HPV vaccine uptake in rural Uganda.BMC pediatrics · 2026Article
- Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bridging the service gap: health facility challenges in HPV vaccine uptake in rural Uganda.BMC women's health · 2026Article
- TMEM132A promotes cervical cancer progression via HOMER3-mediated activation of FAK/PI3K/AKT signaling pathway.Scientific reports · 2026Article
- Urban-rural disparities in HPV prevalence and genotype distribution: a large-scale cervical cancer screening study in Xi'an, China.BMC infectious diseases · 2026Article
- Cervical cancer perceived behavioral risk factors using logistic regression technique.Journal of biomedical research · 2026Article
- Article
- Unveiling TNFRSF19: a novel tumor suppressor targeting endoplasmic reticulum stress and LGR5/Wnt/β-catenin in cervical cancer.Human cell · 2026Article
- Advancing the elimination of cervical cancer across Africa.Nature communications · 2026Review
- Incidence Trends and Geographic Variations of Corpus Uteri and Cervical Cancer in Taiwan, 1995-2022: A Population-Based Study.Cancers · 2026Article
- Highly Sensitive Fluorescent Detection of HPV-16 DNA Using Tungsten Disulfide Nanosheets and Exonuclease III-Assisted Signal Amplification.Biosensors · 2026Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major public health problem, ranking as the fourth most common cause of cancer incidence and mortality in women worldwide. Wide variations in cervical cancer incidence and mortality were observed with highest incidence rates in Sub Saharan Africa and with 85% of deaths occurring in developing regions of the world. Non-existent or inadequate screening in public health care settings and limited access to the standard treatment options explains the large geographic variation in cervical cancer rates. Persistent infection with high-risk Human papillomavirus (HPV) types is the major risk factor for cervical cancer. High parity, long-term use of oral contraceptive pills, tobacco consumption, co-infection with other sexually transmitted agents, lifestyle factors such as multiple sexual partners, younger age at first sexual intercourse, immunosuppression, and diet have been identified as the co-factors most likely to influence the risk of acquisition of HPV infection and its further progress to cervical carcinogenesis. Differential screening rates and changes in epidemiological patterns have contributed to decreasing trends in cervical cancer in some developed regions of the world. Lower rates were also observed in North Africa and the Middle East, which may be attributed to cultural norms and conservative sexual behaviors. Across world regions, HPV prevalence was highest in women younger than 35 years of age, declining to a plateau in middle age and showed significant association between national age standardized incidence rates and corresponding estimates of HPV prevalence. The five most common HPV types in HPV-positive women worldwide were HPV16, HPV18, HPV31, HPV58, and HPV52, representing 50% of all HPV infections with HPV-16 and HPV-18 infections accounting for about 70% of the total infection burden. Tracking changing trends in the cervical cancer epidemiological patterns including HPV genotypes will immensely contribute toward effective prevention and control measures for cervical cancer elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.